Hamad Medical Corporation (HMC) recently held the Medication Safety Symposium 2017 focused on best practices and continuous quality improvement of patient safety in the region.  

The symposium, endorsed by the International Medication Safety Network (IMSN) and Institutes for Safe Medication Practices USA (ISMP) and Canada (ISMP Canada), attracted over 350 delegates.

The HMC Medication Safety Symposium 2017 brought together a group of regional experts and leaders in the field of medication safety. Speakers from various healthcare sectors discussed the best medication safety practices in the region, including pharmacovigilance – the practice of monitoring the effects of medical drugs and its importance to Qatar, medication-use research and other patient-safety initiatives.

Key speakers included Dr Rabih Dabliz, Manager for Quality and Medication Safety Services at Cleveland Clinic Abu Dhabi;  Dr Adel Alharf, Executive Director for Vigilance and Benefit/Risk Assessment Directorate at Saudi Food and Drug Authority (SFDA) and Dr Amr Saad, former Associate Minister of Health for Pharmaceutical Affairs and Founder of the Egyptian Pharmaceutical Vigilance Centre.

Dr Moza Al Hail, Executive Director of Pharmacy at HMC, said that the symposium was a great opportunity for healthcare providers, researchers, and aspiring pharmacists in Qatar to engage in discussions on medication safety. He said that the gathering consolidates HMC’s commitment to providing the safest, most effective and most compassionate care to patients, giving delegates the chance to identify the best medication safety strategies and learn innovative ways of ensuring the safe use of medications.

The symposium was an Accredited Group Learning Activity (Category 1) as defined by the Qatar Council for Healthcare Practitioners – Accreditation Department and approved for seven Continuing Professional Development hours.

For more information, visit hamad.qa